ReviewClinical pharmacokinetics1992
Pharmacokinetic studies in paediatric patients. Clinical and ethical considerations.
Review in Clinical pharmacokinetics, 1992. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 74 citations in OpenAlex.
- Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen.British journal of clinical pharmacology · 2008Trial
- Population pharmacokinetics of pyrimethamine and sulfadoxine in children treated for congenital toxoplasmosis.Antimicrobial agents and chemotherapy · 2004Trial
- Population pharmacokinetics of liposomal daunorubicin in children.British journal of clinical pharmacology · 2003Trial
- Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients.British journal of clinical pharmacology · 2000Trial
- Confirming the Suitability of a Gentamicin Dosing Strategy in Neonates Using the Population Pharmacokinetic Approach with Truncated Sampling Duration.Children (Basel, Switzerland) · 2024Article
- SwissPKCPT: pharmacometrics & systems pharmacology · 2021Article
- Population pharmacokinetics of tacrolimus in pediatric patients with systemic-onset juvenile idiopathic arthritis: Initial dosage recommendations.Experimental and therapeutic medicine · 2019Article
- Population pharmacokinetics of sirolimus in pediatric patients with kaposiform hemangioendothelioma: A retrospective study.Oncology letters · 2019Article
- Population pharmacokinetics of tacrolimus in pediatric refractory nephrotic syndrome and a summary of other pediatric disease models.Experimental and therapeutic medicine · 2019Article
- Cyclosporin population pharmacokinetics in pediatric refractory nephrotic syndrome based on real-world studies: Effects of body weight and spirolactone administration.Experimental and therapeutic medicine · 2019Article
- Pharmacokinetic-Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance.Clinical pharmacokinetics · 2019Review
- Individual and population pharmacokinetic compartment analysis: a graphic procedure for quantification of predictive performance.Journal of drug assessment · 2013Article
- From adults to children: simulation-based choice of an appropriate sparse-sampling schedule.Paediatric drugs · 2012Article
- Off-label and unlicensed drug utilization in hospitalized children in Fortaleza, Brazil.European journal of clinical pharmacology · 2008Article
- Development and evaluation of a generic physiologically based pharmacokinetic model for children.Clinical pharmacokinetics · 2006Article
- The Food and Drug Administration's deliberations on antidepressant use in pediatric patients.Pediatrics · 2005Article
- Transdermal reverse iontophoresis of valproate: a noninvasive method for therapeutic drug monitoring.Pharmaceutical research · 2003Article
- Bayesian forecasting in paediatric populations.Clinical pharmacokinetics · 1996Review
- Paediatric labelling requirements. Implications for pharmacokinetic studies.Clinical pharmacokinetics · 1994Review
- Propofol infusion in children.BMJ (Clinical research ed.) · 1992Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Important advances in paediatric clinical pharmacology have been made over the past 2 decades. However, there remains a reluctance to pursue pharmacodynamic and pharmacokinetic studies in children and, consequently, many important therapeutic agents have not been adequately studied in this population. Age-related pharmacokinetic/pharmacodynamic studies are not only essential to provide optimal drug therapy for children, but are quite feasible. Usually, paediatric pharmacokinetic studies are conducted in children receiving treatment for a specific medical condition. The approach to soliciting participation of paediatric subjects requires special sensitivity to the fears and anxieties of the child and the parents. Factors influencing subject enrollment and suggestions to enhance enrollment into study protocols are discussed. Pharmacokinetic/pharmacodynamic studies require repeated measurements over time and often entail obtaining multiple blood and urine samples. Techniques for reducing sample volume and number of necessary samples while minimising the discomfort and fear associated with obtaining multiple samples include the development of highly sensitive analytical methods to measure drug concentrations in small volume samples. The number of samples obtained from individual subjects can be minimised by using pharmacokinetic analytical approaches such as the nonlinear mixed effect model (NONMEM) which allows estimation of pharmacokinetic characteristics of a population using limited data from each subject. In addition, less invasive methods to measure drug metabolism/elimination such as salivary sampling, transcutaneous collection and breath analysis have been applied to the study of certain drugs. Children are a particularly vulnerable population because of their limited cognitive abilities and dependence on adults. Thus, they must be afforded greater protection from exploitation as research subjects than that provided to adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.